 Sample size and power issues in estimating incremental cost‐effectiveness ratios from clinical trials dataAndrew R. Willan and Bernie J. O'Brien Health Economics, 1999, vol. 8, issue 3, 203-211 Abstract: It is becoming increasingly more common for a randomized controlled trial of a new therapy to include a prospective economic evaluation. The advantage of such trial‐based cost‐effectiveness is that conventional principles of statistical inference can be used to quantify uncertainty in the estimate of the incremental cost‐effectiveness ratio (ICER). Numerous articles in the recent literature have outlined and compared various approaches for determining confidence intervals for the ICER. In this paper we address the issue of power and sample size in trial‐based cost‐effectiveness analysis. Our approach is to determine the required sample size to ensure that the resulting confidence interval is narrow enough to distinguish between two regions in the cost‐effectiveness plane: one in which the new therapy is considered to be cost‐effective and one in which it is not. As a result, for a given sample size, the cost‐effectiveness plane is divided into two regions, separated by an ellipse centred at the origin, such that the sample size is adequate only if the truth lies on or outside the ellipse. Copyright © 1999 John Wiley & Sons, Ltd. Date: 1999 Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:8:y:1999:i:3:p:203-211 Access Statistics for this article Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones More articles in Health Economics from John Wiley & Sons, Ltd. |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.